{"nctId":"NCT03046927","briefTitle":"Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes","startDateStruct":{"date":"2017-10-19","type":"ACTUAL"},"conditions":["Type 1 Diabetes"],"count":48,"armGroups":[{"label":"Ergocalciferol","type":"EXPERIMENTAL","interventionNames":["Drug: Ergocalciferol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Ergocalciferol","otherNames":["Vitamin D"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age: 10-21 years.\n2. Sex: male and female subjects will be enrolled.\n3. Tanner stage: I-V.\n4. T1D duration of \\<3 months (i.e., from first insulin injection) to ensure the inclusion of patients in PCR.\n5. Presence of at least one diabetes-associated autoantibody.\n6. Normal-weight, overweight-, and obese subjects with T1D\n7. Fasting serum C-peptide level of \\>0.1 nmol/L (0.3 ng/mL)1; or 2-hour post-meal stimulated C-peptide level of 0.2 nmol/L (â‰¥0.6 ng/mL).\n\nExclusion Criteria:\n\n1. Subjects on weight altering medications, such as orlistat.\n2. Subjects with eating disorders\n3. Subjects on medications other than insulin that can affect blood glucose level.\n4. Subjects with 25-hydroxyvitamin D \\[25(OH)D\\] levels of \\>70 ng/mL, as this may lead to vitamin D toxicity in the study subjects.\n5. Subjects with systemic diseases other than T1D.\n6. Subjects with recurrent diabetic ketoacidosis (\\>2 episodes since the diagnosis of T1D or in the preceding 3 months); or \\>2 episodes of severe hypoglycemia in the preceding 3 mo.\n7. Pregnant or breast-feeding female subjects.\n8. The receipt of any investigational drug within 6 months prior to this trial.\n9. Active malignant neoplasm.","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Residual Beta-cell Function (RBCF)","description":"Investigation of the effect of vitamin D on residual beta cell function (RBCF) in the first 12 months after the diagnosis of T1D by using stimulated C-peptide levels to quantify RBCF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":"0.28"},{"groupId":"OG001","value":"2.27","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.56","spread":"0.25"},{"groupId":"OG001","value":"1.76","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"0.26"},{"groupId":"OG001","value":"1.53","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.24"},{"groupId":"OG001","value":"1.36","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"0.22"},{"groupId":"OG001","value":"1.15","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Change in Percent of HbA1c From Baseline Over Time During Partial Clinical Remission (PCR)","description":"Effect of vitamin D supplementation on glycemic control during the partial clinical remission phase as shown by the change in percent HbA1c from baseline across longitudinal measurements at 0, 3, 6, 9, and 12 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.62","spread":"0.32"},{"groupId":"OG001","value":"7.47","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.25","spread":"0.37"},{"groupId":"OG001","value":"6.67","spread":"0.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.28","spread":"0.27"},{"groupId":"OG001","value":"7.15","spread":"0.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.48","spread":"0.35"},{"groupId":"OG001","value":"7.61","spread":"0.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.65","spread":"0.57"},{"groupId":"OG001","value":"8.03","spread":"0.41"}]}]}]},{"type":"SECONDARY","title":"Glucagon-like Peptide-1 (GLP-1)","description":"Investigation of the effect of vitamin D supplementation on GLP-1 during PCR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.26","spread":"7.54"},{"groupId":"OG001","value":"5.81","spread":"3.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.58","spread":"5.02"},{"groupId":"OG001","value":"8.4","spread":"5.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.24","spread":"5.69"},{"groupId":"OG001","value":"6.86","spread":"3.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.26","spread":"5.57"},{"groupId":"OG001","value":"8.89","spread":"5.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.11","spread":"4.44"},{"groupId":"OG001","value":"9.63","spread":"5.92"}]}]}]},{"type":"SECONDARY","title":"Vitamin D Binding Protein (VDBP)","description":"Investigation of the effect of vitamin D supplementation on VDBP during PCR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134.32","spread":"22.82"},{"groupId":"OG001","value":"111.56","spread":"28.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118.11","spread":"27.93"},{"groupId":"OG001","value":"118.79","spread":"22.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135.32","spread":"27.51"},{"groupId":"OG001","value":"138.18","spread":"33.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135.79","spread":"38.47"},{"groupId":"OG001","value":"131.51","spread":"38.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141.34","spread":"32.8"},{"groupId":"OG001","value":"152.42","spread":"31.19"}]}]}]},{"type":"SECONDARY","title":"Effect of Vitamin D Supplementation on the Duration of Partial Clinical Remission (PCR) of Type 1 Diabetes","description":"Insulin dose-adjusted hemoglobin A1c (HbA1c) (IDAA1C)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"0.4"},{"groupId":"OG001","value":"9.4","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":"0.6"},{"groupId":"OG001","value":"8.4","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"0.5"},{"groupId":"OG001","value":"9","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"0.5"},{"groupId":"OG001","value":"10.1","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":"0.6"},{"groupId":"OG001","value":"10.7","spread":"0.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":18},"commonTop":["upper respiratory infection","mild hair loss"]}}}